Content about Sagent Pharmaceuticals

SCHAUMBURG, Ill. — Sagent Pharmaceuticals has launched a drug used to treat apnea of prematurity in infants, the drug maker said Wednesday.

Sagent announced the launch of caffeine citrate injection and caffeine citrate oral solution, used to treat apnea of prematurity in infants between 28 and less than 33 weeks gestational age.

The market for the drug was worth about $28.5 million during the 12-month period ended in July, according to IMS Health. The drug features Sagent's PreventIV Measures packaging and labeling, which are designed to reduce medication errors.

 SCHAUMBURG, Ill. — Sagent Pharmaceuticals has launched a drug used to treat complications related to chemotherapy, the drug maker said.

The Schaumburg, Ill.-based company announced the launch of ondansetron injection, used to prevent nausea and vomiting associated with emetogenic cancer chemotherapy and also to prevent nausea and vomiting that follows surgery.

Various versions of the drug had sales of $49 million during the 12-month period that ended in June, according to IMS Health.

SCHAUMBURG, Ill. — Sagent Pharmaceuticals has launched a generic antibiotic, the company said.

The generic drug maker announced the launch of oxacillin for injection. The drug is a semi-synthetic penicillin used to treat infections caused by penicillinase-producing staphylococci bacteria that have demonstrated susceptibility to the drug.

The drug had sales of $29 million during the 12-month period ended in May, according to IMS Health.

SCHAUMBURG, Ill. — Third-quarter net revenue for Sagent Pharmaceuticals jumped 94% to $41.3 million, thanks to several new product launches during the period.

Gross profit for the quarter ended Sept. 30 was $6.9 million, or 16.8% of net revenues, compared with $2.7 million, or 12.9% of net revenues, in the year-ago period.

SCHAUMBURG, Ill. — Sagent Pharmaceuticals has launched its new chemotherapy drug.

Sagent sent that its paclitaxel injection USP is available in 30-mg, 100-mg and 300-mg latex-free, multi-dose vials. Paclitaxel is indicated for use alone or with other drugs to treat ovarian cancer, breast cancer, non-small cell lung cancer and AIDS-related Kaposi's sarcoma, Sagent said.

SCHAUMBURG, Ill. — Jonathon Singer has been appointed CFO of Sagent Pharmaceuticals, the generic drug maker said.

Singer joins Sagent from Landauer, a leader in radiation sciences and services, where he served as SVP finance and CFO. Meanwhile, Sagent's current CFO, Ron Pauli, will be transitioned into a newly created role of chief business officer, where he will be responsible for product launch execution, product pipeline management and business development.

SCHAUMBURG, Ill. — Sagent Pharmaceuticals has increased the number of shares it’s issuing in its initial public offering on the Nasdaq, the drug maker said Wednesday.

Originally planning to offer 5 million shares, the company has increased that number to 5.75 million shares at $16 per share.

The underwriters have a 30-day option to purchase up to an additional 862,500 shares at the IPO price. The offering is expected to close next Tuesday.

SCHAUMBURG, Ill. Generic drug maker Sagent Pharmaceuticals has launched two injectable antibiotics, the company said Tuesday.

Sagent announced the launch of ampicillin and ampicillin with sulbactam. Ampicillin had sales of around $42 million during the 12-month period ended in June, while ampicillin with sulbactam had sales of around $40 million during the same period, according to IMS Health.